Search

Your search keyword '"Luatti, S."' showing total 114 results

Search Constraints

Start Over You searched for: Author "Luatti, S." Remove constraint Author: "Luatti, S."
114 results on '"Luatti, S."'

Search Results

1. Differences among young adults, adults and elderly chronic myeloid leukemia patients

2. Differences among young adults, adults and elderly chronic myeloid leukemia patients

5. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

6. LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FRONTLINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY

7. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

8. Additional chromosomal abnormalities in Ph positive clone: adverse prognostic influence on frontline imatinib therapy, a GIMEMA WP on CML analysis

9. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications

10. GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION

11. Differences among young adults, adults and elderly chronic myeloid leukemia patients

12. Rare High Risk IgH Translocations in Newly Diagnosed Multiple Myeloma (MM): Cytogenetic Characterization and Relevance on Prognosis

13. Results of high dose of imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase trial of the GIMEMA Working Party

15. CHROMOSOME ABNORMALITIES ADDITIONAL TO THE PHILADELPHIA CHROMOSOME AT THE DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA. PATHOGENETIC AND PROGNOSTIC IMPLICATIONS

22. Influence of additional chromosome abnormalities to PH on response to imatinib mesylate therapy in early chronic phase in chronic myeloid leukemia

23. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up (on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia)

24. VARIANT PHILADELPHIA TRANSLOCATION IN EARLY CHRONIC PHASE OF CHRONIC MYELOID LEUKEMIA: RESULTS OF IMATINIB MESYLATE THERAPY (A GIMEMA WP ON CML ANALYSIS)

37. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

38. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

39. A Prospective Study in Ph+ Chronic Myeloid Leukemia (CML) Patients Showing That Interphase Fluorescence in Situ Hybridization (FISH) Is Effective as Conventional Cytogenetics for Definition of Cytogenetic Response. Correlation with Molecular Response (by the GIMEMA CML WP).

43. Imatinib 600 mg in the treatment of chronic myeloid leukemia in accelerated phase and in blast crisis. Results of a multicentric prospective study of the GIMEMA working party of civil in the long term

45. CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH IMATINIB MESYLATE

48. Differences among young adults, adults and elderly chronic myeloid leukemia patients

49. t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities

50. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA WP on CML analysis

Catalog

Books, media, physical & digital resources